Stocksigma LogoStocksigma Logo

CARE Ratings Revises Mukka Proteins' Outlook to Stable; Reaffirms Ratings

CARE Ratings reaffirmed Mukka Proteins Limited’s bank facilities at CARE BBB-/CARE A3, revising the outlook to Stable from Negative on 7th Oct'26

CARE Ratings Revises Mukka Proteins' Outlook to Stable; Reaffirms Ratings

Mukka Proteins Ltd · Others (Uncategorized) · 07 Oct 2026, 10:15 pm

CARE Ratings Revises Mukka Proteins' Outlook to Stable; Reaffirms Ratings CARE Ratings reaffirmed Mukka Proteins Limited’s bank facilities at CARE BBB-/CARE A3, revising the outlook to Stable from Negative on 7th Oct'26. The revision reflects strong Q1FY27 performance, where consolidated revenue jumped ~187% YoY to ₹490 crore, driven by a ~93% increase in realisations and ~49% volume growth with PBILDT margins above 9%. Liquidity is supported by ₹47 crore raised via equity warrants and an unexecuted order book of ₹500–550 crore, offset by high working capital intensity and raw material price volatility.

Original exchange filing (PDF)

More announcements from Mukka Proteins Ltd

All Mukka Proteins Ltd announcements